Nanobiomedicine (NAB) is a peer-reviewed, open access journal which focusses on research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Please see the Aims and Scope tab for further information.
This journal is a member of the Committee on Publication Ethics (COPE)
Why publish in Nanobiomedicine?
- Expert international Editorial Board
- Rigorous peer review of your scholarly work
- Reaches inter-professional audiences
Open access article processing charge (APC) information
The article processing charge (APC) for this journal is currently 1500 USD, discounted from the full rate of 2000 USD.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Submit your manuscript today at http://mc.manuscriptcentral.com/nanobiomedicine.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Please direct any queries to Philippa.email@example.com
Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered.
All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles.
Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to:
- Nanoscale-structured biomaterials
- Nanoscale bio-devices
- Nanoscale imaging
- Nanoscale drug delivery
- Nanosensors (nanowires, nanophotonics)
- Nanosurgery (dermatology, gastroenterology, ophthalmology, etc)
- Nanocarriers commercialization of nanobiomedical technologies
- Market trends in the nanobiomedicine space
- Ethics and regulatory aspects of nanobiomedicine approval
- New perspectives of nanobiomedicine in clinical diagnostics
- Nanoscale visualization
|Prof. Winston Kuo||CloudHealth Genomics, Ltd., China|
|Dr. Peter Burkhard||University of Connecticut, USA|
|Dr. Thomas Ming Swi Chang||Artificial Cells & Organs Research Centre, McGill University, Canada|
|Dr. Yong Chen||Ecole normale superieure, France|
|Dr. Utkan Demirci||Stanford University, USA|
|Dr. Toshio Fukuda||Nagoya University, Japan|
|Dr Zhenghong Gao||University of Michigan, USA|
|Dr. Umut Gurkan||Case Western Reserve University, USA|
|Dr. Hossam Haick||Isreal Institute of Technology, Israel|
|Dr. Karsten König||Saarland University, Germany|
|Dr. Steven Little||University of Pittsburgh, USA|
|Dr. Marko Loncar||Harvard University, USA|
|Prof. Ian Nicholls||Linnaeus University, Sweden|
|Dr. Martin Pumera||Nanyang Technological University, Singapore|
|Dr. Alexander Seifalian||University College London, UK|
|Dr. Molly Shoichet||Univeristy of Toronto, Canada|
|Dr. Brian Thrall||Pacific Northwest National Laboratory, USA|
|Dr. Demir Akin||Stanford University, USA|
|Dr. Omar Ali||OS Fund, USA|
|Dr. Kirk Andriano||Elute Inc, USA|
|Dr. Giuseppe Bardi||Istituto Italiano di Tecnologia, Italy|
|Dr. Bharat Bhushan||The Ohio State University, USA|
|Dr. Adriano Cavalcanti||Center for Automation in Nanobiotech, Australia|
|Dr. Hicham Fenniri||Northeastern University, United States, USA|
|Dr. Xiaohu Gao||University of Washington, USA|
|Dr. Peixuan Guo||The Ohio State University, USA|
|Dr. Kutay Icoz||Abdullah Gül Üniversitesi, Turkey|
|Dr. Esmaiel Jabbari||University of South Carolina, USA|
|Dr. Ali Khademhosseini||Harvard Medical School, United States, USA|
|Dr. Vipuil Kishore||Florida Institute of Technology, United States, USA|
|Dr. Seda Kizilel||Koc University, Turkey|
|Dr. Alexander Lazarev||Pressure BioSciences, USA|
|Dr. Didier Letourneur||INSERM, France|
|Dr. Allen Nicholson||Temple University, USA|
|Dr. Hyungyu Park||Korea Advanced Institute for Science and Technology, South Korea|
|Dr. Steffen Petersen||Aalborg University, Denmark|
|Dr. Pier Paolo Pompa||Italian Institute of Technology, Italy|
|Dr. Hao Qi||University of Tokyo, Japan|
|Dr. Fabiana Quaglia||University of Naples Federico II, Italy|
|Dr. Qimin Quan||Rowland Institute at Harvard University, USA|
|Dr. Francesca Re||University of Milano Bicocca, Italy|
|Dr. Angel Sacido||Hospital de Madrid Foundation, Spain|
|Dr. Giacinto Scoles||Scuola Internazionale Superiore de Studi Avanzati, Trieste, Italy|
|Dr. Shiladitya Sengupta||Brigham & Women's Hospital and Harvard Medical School, USA|
|Dr. Barbara Smith||Arizona State University, USA|
|Dr. Yu Sun||University of Toronto, Canada|
|Dr. Weihong Tan||University of Florida, USA|
|Dr. Suresh Valiyaveettil||National Univeristy of Singapore, Singapore|
|Dr. Frank Vollmer||Max Planck Institute for the Science of Light, Germany|
|Dr. Shuqi Wang||Stanford University, USA|
|Dr. Zhongcong Xie||Massachusetts General Hospital, USA|
|Dr. Feng Xu||Xi'an Jiaotong University, China|
|Dr. Xiaohui Zhang||Chinese Academy of Science, China|
|Dr. Pinar Zorlutuna||University of Notre Dame, USA|
- Open Access
- Article processing charge (APC)
- Article Types
- Editorial policies
4.1 Peer Review Policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
- Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.2 Information required for completing your submission
7.3 Corresponding author contact details
- On acceptance and publication
8.1 SAGE Production
8.2 Continuous publication
8.3 Promoting your article
- Further information
This Journal is a member of the Committee on Publication Ethics.
Please read the guidelines below then visit the journal’s submission site http://mc.manuscriptcentral.com/Nanobiomedicine to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Only manuscripts of sufficient quality that meet the aims and scope of Nanobiomedicine will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Nanobiomedicine is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
There will be no article processing charge (APC) for a limited time while the journal is being established. SAGE will cover all costs. In the future, it is expected that an APC will be charged as part of a plan for ensuring sustainability of the journal.
The article processing charge (APC) for this journal is currently 1500 USD, discounted from the full rate of 2000 USD.
Original Research Article
Article that presents original research work, reporting the results of one or more empirical studies or experiments.
These articles are original communications of 1 to 4 pages in length. The scope of these articles is to disseminate authors' perspectives and brief observations that do not fit full length papers, but that represent new achievements in the field to be developed in detail and reported thoroughly elsewhere.
Invited Feature Article
Article intended to provide readers with in-depth analysis and discussion around new advances, usually commissioned from an expert in the field.
Perspectives present an opinion, hypothesis, or historical account related to nanotechnology and biomedical research, ranging from translational and clinical applications that address diagnosis, delivery of therapeutics, drug delivery and monitoring of human diseases. Prospective authors are strongly encouraged to submit a pre-submission inquiry to the Editors-in-Chief that describes the topic and scope of the proposed perspective.
Invited Review Article
Solicited by the Editors-in-Chief, Invited Review Articles should present an overview of the most recent advances in a given research area, including current debates and ideas of the area’s future direction. Prospective authors must submit a pre-submission inquiry to the Editors-in-Chief, describing the topic and scope of the proposed review, which the Editors-in-Chief may choose to either invite or decline.
Articles written for and presented at an academic conference. If your article is based on a conference paper that may have been published elsewhere, please ensure that the new article differs substantially from the conference paper or presentation it is based upon. Differences should be described in detail in the Cover Letter accompanying the submission, and the Acknowledgments section of the manuscript should include the following statement:
"'This article is a revised and expanded version of a paper entitled [title] presented at [name, location and date of conference]."
Original Research Articles should be 4 to 12 pages in length, including references, whereas other article types may be shorter.
Following a preliminary triage to eliminate submissions unsuitable for Nanobiomedicine all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why. The journal’s policy is to have manuscripts reviewed by two expert reviewers. Nanobiomedicine utilizes a double-blind peer review process in which the reviewer and author’s names and information are withheld from the other. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editors-in-Chief who then makes the final decision.
As part of the submission process you will be asked to provide the names of 2 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).
Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
- Disclose this type of editorial assistance – including the individual’s name, company and level of input
- Identify any entities that paid for this assistance
- Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
4.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).
It is not necessary to disclose use of language polishing services.
Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.
Nanobiomedicine requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Nanobiomedicine to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
Nanobiomedicine conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Nanobiomedicine and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Nanobiomedicine publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in colour will appear in colour online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Nanobiomedicine adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Nanobiomedicine is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/Nanobiomedicine to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been check for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Nanobiomedicine editorial office as follows: